企業プロフィール
Longeveron 株価・ニュース・カタリスト
- ティッカー:
- LGVN
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
0.84 USD (+2.02%)
終値
最終更新: 2026年8月21日
24M USD
時価総額
株価変動の要因
The latest monitored company update is “Longeveron Announces 1-for-10 Reverse Stock Split.” The corresponding closing-price reaction is not yet available.
企業概要
Regenerative Medicine Company
Longeveron develops allogeneic cellular therapies for rare pediatric and chronic aging-related conditions.
Laromestrocel
Laromestrocel, formerly Lomecel-B, is manufactured from bone marrow-derived medicinal signaling cells obtained from young healthy adult donors.
Hypoplastic Left Heart Syndrome
The ELPIS program evaluates laromestrocel as an adjunct to staged surgery in infants with hypoplastic left heart syndrome, an orphan pediatric condition.
Additional Regenerative Applications
The company is also exploring laromestrocel in aging-related and neurological conditions where inflammation and impaired tissue repair may contribute to disease.
今後のカタリスト
- Topline results from the Phase 2b ELPIS II study in hypoplastic left heart syndrome are expected in August 2026.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。